{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-6.76","upperLimit":"-2.83","value":"-4.795"},{"groupId":"OG001","lowerLimit":"-6.75","upperLimit":"-2.98","value":"-4.865"}]}],"title":"Disease Symptom wk 12 change baseline (n=215,243)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-6.53","upperLimit":"-2.27","value":"-4.401"},{"groupId":"OG001","lowerLimit":"-8.79","upperLimit":"-4.81","value":"-6.797"}]}],"title":"Disease Symptom wk 24 change baseline (n=148,177)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-6.76","upperLimit":"-1.084","value":"-2.836"},{"groupId":"OG001","lowerLimit":"-11.1","upperLimit":"-2.12","value":"-6.626"}]}],"title":"Disease Symptom wk 48 change baseline (n=37,26)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.510","upperLimit":"9.814","value":"8.162"},{"groupId":"OG001","lowerLimit":"3.933","upperLimit":"7.115","value":"5.524"}]}],"title":"Side effects of treatment wk 12 chge (n=213,242)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.955","upperLimit":"11.08","value":"9.016"},{"groupId":"OG001","lowerLimit":"5.795","upperLimit":"9.668","value":"7.731"}]}],"title":"Side effects of treatment wk 24 chge (n=148,175)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.442","upperLimit":"6.273","value":"3.357"},{"groupId":"OG001","lowerLimit":"0.352","upperLimit":"6.956","value":"3.654"}]}],"title":"Side effects of treatment wk 48 chge (n=37,26)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.893","upperLimit":"7.744","value":"5.319"},{"groupId":"OG001","lowerLimit":"3.854","upperLimit":"8.533","value":"6.194"}]}],"title":"Future perspective wk 12 chge (n=214,242)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.977","upperLimit":"6.778","value":"3.877"},{"groupId":"OG001","lowerLimit":"3.103","upperLimit":"8.575","value":"5.839"}]}],"title":"Future perspective wk 24 chge (n=148,176)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-.142","upperLimit":"8.804","value":"4.331"},{"groupId":"OG001","lowerLimit":"1.807","upperLimit":"12.10","value":"6.951"}]}],"title":"Future perspective wk 48 chge (n=37,26)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-10.5","upperLimit":"-3.87","value":"-7.178"},{"groupId":"OG001","lowerLimit":"-9.41","upperLimit":"-3.03","value":"-6.22"}]}],"title":"Body image wk 12 chge (n=213,240)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-15.3","upperLimit":"-7.66","value":"-11.463"},{"groupId":"OG001","lowerLimit":"-10.9","upperLimit":"-3.81","value":"-7.358"}]}],"title":"Body image wk 24 chge (n=147,175)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-7.73","upperLimit":"3.410","value":"-2.161"},{"groupId":"OG001","lowerLimit":"-11.1","upperLimit":"1.729","value":"-4.666"}]}],"title":"Body image wk 48 chge (n=37,26)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"387"},{"groupId":"OG001","value":"381"}],"units":"Participants"}],"description":"Higher values in the disease symptoms and side effects of treatment scores indicate worsening. Higher scores in the future perspective and body image scores indicate improvement. LS Means and SEM are estimated from the repeated measures model. Following factors and covariates are included in the repeated measurement model: time, treatment, treatment by time interaction, number of prior lines of anti-MM therapy (1/ 2 and 3), prior use of BTZ (Yes/ No), baseline score.Disease Symptom is the sum of 20 questions, total score ranges from 0 (best possible outcome) to 100 (worst possible outcome)\", All subscales of EORTC QLQ-MY20 have the same score range of 0 -100. Decrease in symptom scores from baseline indicate improvement in symptoms.","dispersionType":"95% Confidence Interval","groups":[{"description":"Panobinostat was given 20 mg hard gelatin capsules . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV)injection. Dexamethasone was given as an oral dose of 20 mg/day.","id":"OG000","title":"Panobinostat + Bortezomib"},{"description":"Placebo was given as a hard gelatin capsule in the image of Panobinostat . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV) injection. Dexamethasone was given as an oral dose of 20 mg/day.","id":"OG001","title":"Placebo + Bortezomib"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Full Analysis Set","reportingStatus":"POSTED","timeFrame":"12, 24 and 48 weeks","title":"European Organization for Research and Treatment of Cancer Multiple Myeloma Module (EORTC) QLQ-MY20-Change From Baseline by Treatment Group","type":"SECONDARY","unitOfMeasure":"score on a scale"}